CHF 40,000 for a device for rapid on-site drug detection and comprehensive fetal-maternal monitoring
14.08.2025
Altiscreen and VidaSense were selected at Venture Kick's second stage of financial and entrepreneurial support. Their projects offer a truly portable, easy-to-use device for rapid, on-site drug detection; and deliver comprehensive fetal-maternal monitoring through a non-invasive, lightweight wearable device.
 |
 |
 Altiscreen: CEO Leonard Dumea
|
|
 VidaSense: CEO Dr. Naeimeh Behbood & CTO Dr. Gürkan Yilmaz
|
|
Altiscreen: Transforming Handheld Drugs of Abuse Screening
Altiscreen is addressing the critical need for rapid, on-site drug detection to help reduce healthcare costs, workplace accidents, and road fatalities. The company provides a truly portable and user-friendly device that delivers accurate results in just minutes, in contrast to existing solutions that are often bulky, slow, or complex.
Founded by Dr. Leonard Dumea in 2024, Altiscreen has developed a device that utilizes advanced immuno-chromatographic methods and image recognition technology. This innovative solution delivers results quickly and is compatible with various sample types, including oral fluid and urine. The device can detect up to nine substances simultaneously and has been field-validated with clients.
The drug testing market is projected to reach USD 11.9 billion by 2030, with significant growth opportunities for handheld testing in Europe.
Funding from Venture Kick will enable Altiscreen to produce its first commercial batch and enhance business development. This support will accelerate manufacturing, market entry, and partnerships, helping to bring its rapid and portable drug detection device to market.
VidaSense: Comfort in fetal-maternal monitoring, confidence in prenatal care
Existing fetal monitoring devices primarily use ultrasound technology, which presents several limitations. These include high sensitivity to sensor positioning, the need for gel, bulky equipment design, restricted mobility for expectant mothers, and the requirement for frequent readjustments by healthcare personnel.
VidaSense is addressing these challenges in prenatal care by merging comfort with clinical reliability. Their innovative active dry electrode technology enables comprehensive fetal-maternal monitoring through a non-invasive, lightweight wearable device. Behbood and Yilmaz, in collaboration with CSEM and Insel Spital, are advancing this innovation to meet the growing demand for remote monitoring, representing a potential market of USD 1.3 billion worldwide.
The grant provided by VentureKick is crucial for enhancing the system's usability and for onboarding an experienced industrial designer to assist with the mechanical design and the development of a functional prototype for VidaSense.
Altiscreen is addressing the critical need for rapid, on-site drug detection to help reduce healthcare costs, workplace accidents, and road fatalities. The company provides a truly portable and user-friendly device that delivers accurate results in just minutes, in contrast to existing solutions that are often bulky, slow, or complex.
Founded by Dr. Leonard Dumea in 2024, Altiscreen has developed a device that utilizes advanced immuno-chromatographic methods and image recognition technology. This innovative solution delivers results quickly and is compatible with various sample types, including oral fluid and urine. The device can detect up to nine substances simultaneously and has been field-validated with clients.
The drug testing market is projected to reach USD 11.9 billion by 2030, with significant growth opportunities for handheld testing in Europe.
Funding from Venture Kick will enable Altiscreen to produce its first commercial batch and enhance business development. This support will accelerate manufacturing, market entry, and partnerships, helping to bring its rapid and portable drug detection device to market.
VidaSense: Comfort in fetal-maternal monitoring, confidence in prenatal care
Existing fetal monitoring devices primarily use ultrasound technology, which presents several limitations. These include high sensitivity to sensor positioning, the need for gel, bulky equipment design, restricted mobility for expectant mothers, and the requirement for frequent readjustments by healthcare personnel.
VidaSense is addressing these challenges in prenatal care by merging comfort with clinical reliability. Their innovative active dry electrode technology enables comprehensive fetal-maternal monitoring through a non-invasive, lightweight wearable device. Behbood and Yilmaz, in collaboration with CSEM and Insel Spital, are advancing this innovation to meet the growing demand for remote monitoring, representing a potential market of USD 1.3 billion worldwide.
The grant provided by VentureKick is crucial for enhancing the system's usability and for onboarding an experienced industrial designer to assist with the mechanical design and the development of a functional prototype for VidaSense.